BACKGROUND: The role of the adenosine (ADO) suppression pathway, specifically CD39-expressing and CD73-expressing CD4⁺ T cells in HIV-1 infection is unclear. METHODS: We evaluated the frequency and numbers of CD4⁺CD39⁺ and CD4⁺CD73⁺ T cells, activated T cells, and plasma C reactive protein (CRP) levels in 36 HIV-1-positive individuals and 10 normal controls (NC). Low-level plasma viremia was evaluated using single copy assay. Mass spectrometry was used to measure hydrolysis of ATP by ectoenzyme-expressing CD4⁺ T cells, whereas cyclic adenosine monophosphate (cAMP) levels were measured using enzyme immunoassay. Suppression of T-cell function by exogenous ADO and CD4⁺CD73⁺ T cells was tested by flow cytometry. RESULTS: CD39 and CD73 are expressed in different CD4⁺ T-cell subsets. CD4⁺CD73⁺ T cells do not express CD25 and FOXP3, and their frequency and numbers were lower in HIV-1-positive individuals regardless of virologic suppression (P=0.005 and P<0.001, respectively). CD4⁺CD73⁺ numbers inversely correlated with CD4⁺CD38⁺DR⁺ (P=0.002), CD8⁺CD38⁺DR⁺ T-cell frequency (P=0.05), and plasma CRP levels (P=0.01). Both subsets are required for hydrolysis of exogenous ATP to ADO and can increase CD4⁺ T-cell cAMP levels when incubated with exogenous ATP. Low-level viremia did not correlate with activated T-cell frequency. In vitro, ADO suppressed T-cell activation and cytokine expression. CD4⁺CD7⁺ T cells suppressed T-cell proliferation only in the presence of exogenous 5'-AMP. CONCLUSION: The ADO-producing CD4⁺CD73⁺ subset of T cells is depleted in HIV-1-positive individuals regardless of viral suppression and may play a key role in controlling HIV-1-associated immune activation.
BACKGROUND: The role of the adenosine (ADO) suppression pathway, specifically CD39-expressing and CD73-expressing CD4⁺ T cells in HIV-1 infection is unclear. METHODS: We evaluated the frequency and numbers of CD4⁺CD39⁺ and CD4⁺CD73⁺ T cells, activated T cells, and plasma C reactive protein (CRP) levels in 36 HIV-1-positive individuals and 10 normal controls (NC). Low-level plasma viremia was evaluated using single copy assay. Mass spectrometry was used to measure hydrolysis of ATP by ectoenzyme-expressing CD4⁺ T cells, whereas cyclic adenosine monophosphate (cAMP) levels were measured using enzyme immunoassay. Suppression of T-cell function by exogenous ADO and CD4⁺CD73⁺ T cells was tested by flow cytometry. RESULTS:CD39 and CD73 are expressed in different CD4⁺ T-cell subsets. CD4⁺CD73⁺ T cells do not express CD25 and FOXP3, and their frequency and numbers were lower in HIV-1-positive individuals regardless of virologic suppression (P=0.005 and P<0.001, respectively). CD4⁺CD73⁺ numbers inversely correlated with CD4⁺CD38⁺DR⁺ (P=0.002), CD8⁺CD38⁺DR⁺ T-cell frequency (P=0.05), and plasma CRP levels (P=0.01). Both subsets are required for hydrolysis of exogenous ATP to ADO and can increase CD4⁺ T-cell cAMP levels when incubated with exogenous ATP. Low-level viremia did not correlate with activated T-cell frequency. In vitro, ADO suppressed T-cell activation and cytokine expression. CD4⁺CD7⁺ T cells suppressed T-cell proliferation only in the presence of exogenous 5'-AMP. CONCLUSION: The ADO-producing CD4⁺CD73⁺ subset of T cells is depleted in HIV-1-positive individuals regardless of viral suppression and may play a key role in controlling HIV-1-associated immune activation.
Authors: W G Gutheil; M Subramanyam; G R Flentke; D G Sanford; E Munoz; B T Huber; W W Bachovchin Journal: Proc Natl Acad Sci U S A Date: 1994-07-05 Impact factor: 11.205
Authors: Marta Catalfamo; Christopher Wilhelm; Lueng Tcheung; Michael Proschan; Travis Friesen; Jung-Hyun Park; Joseph Adelsberger; Michael Baseler; Frank Maldarelli; Richard Davey; Gregg Roby; Catherine Rehm; Clifford Lane Journal: J Immunol Date: 2011-01-21 Impact factor: 5.422
Authors: Tianyu He; Egidio Brocca-Cofano; Delbert G Gillespie; Cuiling Xu; Jennifer L Stock; Dongzhu Ma; Benjamin B Policicchio; Kevin D Raehtz; Charles R Rinaldo; Cristian Apetrei; Edwin K Jackson; Bernard J C Macatangay; Ivona Pandrea Journal: J Virol Date: 2015-07-15 Impact factor: 5.103
Authors: Daniela F Passos; Viviane M Bernardes; Jean L G da Silva; Maria R C Schetinger; Daniela Bitencourt Rosa Leal Journal: Purinergic Signal Date: 2018-08-10 Impact factor: 3.765
Authors: Bernard J C Macatangay; Edwin K Jackson; Kaleab Z Abebe; Diane Comer; Joshua Cyktor; Cynthia Klamar-Blain; Luann Borowski; Delbert G Gillespie; John W Mellors; Charles R Rinaldo; Sharon A Riddler Journal: J Infect Dis Date: 2020-04-27 Impact factor: 5.226
Authors: Arcadio Agudelo-Hernandez; Yue Chen; Arlene Bullotta; William G Buchanan; Cynthia R Klamar-Blain; Luann Borowski; Sharon A Riddler; Charles R Rinaldo; Bernard J C Macatangay Journal: AIDS Date: 2017-09-24 Impact factor: 4.177
Authors: P J Schuler; Z Saze; C-S Hong; L Muller; D G Gillespie; D Cheng; M Harasymczuk; M Mandapathil; S Lang; E K Jackson; T L Whiteside Journal: Clin Exp Immunol Date: 2014-08 Impact factor: 4.330